Cargando…

Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection()

Detalles Bibliográficos
Autores principales:	Figuero-Pérez, Luis, Olivares-Hernández, Alejandro, Escala-Cornejo, Roberto A., Cruz-Hernández, Juan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226967/ https://www.ncbi.nlm.nih.gov/pubmed/35760706 http://dx.doi.org/10.1016/j.reumae.2022.02.001

Ejemplares similares

Uso de anakinra en el tratamiento de la infección respiratoria grave por SARS-CoV-2
por: Figuero-Pérez, Luis, et al.
Publicado: (2023)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()
por: Figuero-Pérez, Luis, et al.
Publicado: (2021)

Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab
por: Figuero-Pérez, Luis, et al.
Publicado: (2021)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Evaluation of cleaning and disinfection protocols for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) on different hospital surfaces
por: Barrios Andrés, José Luis, et al.
Publicado: (2021)

Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021)

Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2022)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Outcome of patients receiving V-V ECMO for SARS-CoV-2 severe acute respiratory failure
por: Morris, I.S., et al.
Publicado: (2023)

Alpha-1 antitrypsin as a risk marker in SARS-CoV-2 infection
por: Hernández Pérez, José María, et al.
Publicado: (2021)

Strengths and weaknesses of the diagnostic tests for SARS-CoV-2 infection()
por: Hernández-Pérez, José María, et al.
Publicado: (2020)

Myopathy associated with severe SARS-CoV-2 infection
por: Abenza Abildúa, M.J., et al.
Publicado: (2020)

Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
por: Pontali, Emanuele, et al.
Publicado: (2020)

Origin of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and COVID-19
por: Byard, Roger W., et al.
Publicado: (2020)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

TNF-α Levels in Respiratory Samples Are Associated with SARS-CoV-2 Infection
por: Pereson, Matias J., et al.
Publicado: (2022)

Inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by gaseous ozone treatment
por: Yano, H., et al.
Publicado: (2020)

Characteristics of Pleural Effusion in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pneumonia
por: Chong, Woon H., et al.
Publicado: (2021)

Iodine mouthwashes as deterrents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
por: Blasi, Claudio
Publicado: (2020)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: Is Sequela the Bigger Threat?
por: Rai, Nitin, et al.
Publicado: (2021)

Use of oral antiseptics for SARS-CoV-2 infection()
por: Palop Larrea, Vicente, et al.
Publicado: (2020)

Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients
por: Piconi, Stefania, et al.
Publicado: (2023)

Letter to the Editor: “Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Traumatic Cervical Acute Spinal Cord Injury: An Appraisal”
por: Moscote-Salazar, Luis Rafael, et al.
Publicado: (2021)

Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2
por: Pavoni, Vittorio, et al.
Publicado: (2020)

False positives in SARS-CoV-2 disease()
por: Pardo-Lledias, Javier, et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Associated with Rhabdomyolysis and Acute Kidney Injury (AKI)
por: Chong, Woon H., et al.
Publicado: (2020)

Prolonged incubation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a patient on rituximab therapy
por: Koff, Alan G., et al.
Publicado: (2020)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Contamination of High-touch Surfaces in Field Settings*
por: Gholipour, Sahar, et al.
Publicado: (2020)

SARS-CoV-2–Related Acute Respiratory Distress Syndrome Uncovers a Patient with Severe Combined Immunodeficiency Disease
por: Al-Saud, Bandar, et al.
Publicado: (2021)

Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure
por: Masotti, Luca, et al.
Publicado: (2022)

Cardiopulmonary exercise test in patients with post SARS-CoV-2 sequelae: need to create a multicenter working group
por: Vannini, Luca, et al.
Publicado: (2023)

Jaundice in a patient treated with Anakinra in a context of Covid-19
por: Tarhini, H., et al.
Publicado: (2021)

Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report
por: Karadeniz, Hazan, et al.
Publicado: (2020)

Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Coinfection between SARS‐CoV‐2 and other respiratory tract viruses
por: Özdemir, Öner, et al.
Publicado: (2022)

Indication of high-flow oxygen therapy in patients with SARS-CoV-2 pneumonia()
por: Belenguer-Muncharaz, A., et al.
Publicado: (2022)

Lower respiratory tract and plasma SARS-CoV-2 RNA load in critically ill adult COVID-19 patients: Relationship with biomarkers of disease severity
por: Olea, Beatriz, et al.
Publicado: (2021)

Psychosis After Infection With SARS-CoV-2 in an Adolescent: A Case Report
por: Thomas, Reena, et al.
Publicado: (2022)

Letter to the Editor: Embracing Disruptive Change During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic
por: Hess, Ryan, et al.
Publicado: (2020)

An overview of research on air and environmental contamination with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in healthcare settings
por: Kanamori, Hajime
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a43tk68jbk6sov239brkelf455